Detailed Mechanism Funding and Narrative

Years of mechanism: 2015 2016 2017 2018 2019 2020

Details for Mechanism ID: 18096
Country/Region: Democratic Republic of the Congo
Year: 2016
Main Partner: Columbia University
Main Partner Program: International Center for AIDS Care and Treatment Programs
Organizational Type: University
Funding Agency: HHS/CDC
Total Funding: $8,793,191 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $981,229
Care: Orphans and Vulnerable Children (HKID) $281,435
Care: TB/HIV (HVTB) $1,100,000
Care: Pediatric Care and Support (PDCS) $366,337
Laboratory Infrastructure (HLAB) $102,500
Health Systems Strengthening (OHSS) $96,826
Biomedical Prevention: Injection Safety (HMIN) $54,462
Testing: HIV Testing and Counseling (HVCT) $150,000
Sexual Prevention: Other Sexual Prevention (HVOP) $500,000
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $421,756
Treatment: Adult Treatment (HTXS) $4,188,646
Treatment: Pediatric Treatment (PDTX) $550,000
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2017 12,388
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2017 8,256
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2017 167,025
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2017 61,621
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2017 249,290
HTS_TST Service Delivery Point (Facility): Index testing 2017 1,616
HTS_TST Service Delivery Point (Facility): Inpatient 2017 38,650
HTS_TST Service Delivery Point (Facility): Malnutrition facilities 2017 14,490
HTS_TST Service Delivery Point (Facility): Other PITC 2017 14,490
HTS_TST Service Delivery Point (Facility): Outpatient 2017 90,185
HTS_TST Service Delivery Point (Facility): Pediatric 2017 18,573
HTS_TST Service Delivery Point (Facility): PMTCT 2017 65,582
HTS_TST Service Delivery Point (Facility): TB Clinics 2017 4,090
HTS_TST Service Delivery Point (Facility): VCT 2017 1,614
HTS_TST Sum of Aggregated Age/Sex <15 2017 20,644
HTS_TST Sum of Aggregated Age/Sex 15+ 2017 228,646
HTS_TST Sum of Aggregated Age/Sex disaggregates 2017 249,290
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Female 2017 403
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Male 2017 270
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Female 2017 4,349
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Male 2017 2,290
KP_PREV By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2017 8,050
KP_PREV By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2017 1,450
KP_PREV Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required 2017 9,500
KP_PREV Total estimated number of key population in the catchment area 2017 11,876
KP_PREV_den By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area) 2017 10,062
KP_PREV_den By key population type: Men who have sex with men who are sex workers (Denominator: Total estimated number of key population in the catchment area 2017 1,814
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 117
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program 2017 144
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that perform this testing 2017 197
OVC_SERV By Aggregated Age/Sex: <18 Female 2017 1,111
OVC_SERV By Aggregated Age/Sex: <18 Male 2017 741
OVC_SERV Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS 2017 1,852
PMTCT_ART Already on ART at beginning of current pregnancy 2017 212
PMTCT_ART New on ART 2017 872
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 65,874
PMTCT_EID By infants who received a virologic test within 2 months of birth 2017 479
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2017 573
PMTCT_EID Number of infants with a positive virological test result within 12 months of birth 2017 8
PMTCT_EID Number of infants with a positive virological test result within 2 months of birth 2017 7
PMTCT_EID Sum of Infant Age disaggregates 2017 1,052
PMTCT_STAT By: Known positives at entry 2017 281
PMTCT_STAT By: Number of new positives identified 2017 825
PMTCT_STAT Number of new ANC and L&D clients 2017 67,909
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 65,874
PMTCT_STAT Sum of Positives Status disaggregates 2017 1,106
TB_ART Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 23
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 224
TB_ART Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 29
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 292
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2017 630
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2017 568
TB_SCREENDX [Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB 2017 2,725
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert) 2017 151
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only 2017 2,271
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay 2017 303
TB_SCREENDX Screen Result: Screened Positive for TB 2017 3,028
TB_SCREENDX Screened for TB by Age/Sex: 15+ Female 2017 5,904
TB_SCREENDX Screened for TB by Age/Sex: 15+ Male 2017 7,872
TB_SCREENDX Screened for TB by Age/Sex:<15 Female 2017 607
TB_SCREENDX Screened for TB by Age/Sex:<15 Male 2017 756
TB_SCREENDX The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period 2017 15,139
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 153
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 1,514
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 188
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 2,027
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2017 3,882
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2017 4,074
TX_CURR Age/Sex: <1 2017 2
TX_CURR Age/Sex: 10-14 Female 2017 2
TX_CURR Aggregated Age/Sex: <15 Female 2017 1,405
TX_CURR Aggregated Age/Sex: <15 Male 2017 933
TX_CURR Aggregated Age/Sex: 15+ Female 2017 12,306
TX_CURR Aggregated Age/Sex: 15+ Male 2017 4,287
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2017 18,931
TX_CURR Sum of Aggregated Age/Sex <15 2017 2,338
TX_CURR Sum of Aggregated Age/Sex 15+ 2017 16,593
TX_CURR Sum of Aggregated Age/Sex disaggregates 2017 18,931
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2017 364
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2017 242
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2017 4,357
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2017 1,741
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2017 6,704
TX_NEW Sum of Aggregated Age/Sex disaggregates 2017 6,704
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2017 13,254
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2017 9,279
TX_PVLS Numerator Aggregated Age/Sex: <15 Female 2017 558
TX_PVLS Numerator Aggregated Age/Sex: <15 Male 2017 368
TX_PVLS Numerator Aggregated Age/Sex: 15+ Female 2017 6,033
TX_PVLS Numerator Aggregated Age/Sex: 15+ Male 2017 2,320
TX_PVLS Numerator: Indication: Routine 2017 9,083
TX_PVLS Numerator: Indication: Targeted 2017 196
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Female 2017 795
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Male 2017 531
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Female 2017 8,616
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Male 2017 3,312
TX_PVLS_den Denominator: Indication: Routine 2017 12,977
TX_PVLS_den Denominator: Indication: Targeted 2017 277
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 170
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 113
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 1,873
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 722
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2017 2,878
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2017 3,596
TX_RET_den Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 16
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 213
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 145
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 2,340
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 898
Cross Cutting Budget Categories and Known Amounts Total: $264,000
Human Resources for Health $50,000
Key Populations: MSM and TG $30,000
Training of health workers and community outreach workers
Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Collection and use of strategic information
Monitoring and evaluation of MSM/TG programs
Procurement of condoms, lubricants, and other commodities essential to core HIV services for MSM/TG
Gender: Gender Equality $20,000
Increase gender-equitable access to income and productive resources, including education
Condoms: Policy, Tools, and Services $5,000
Motor Vehicles: Purchased $159,000